To Evaluate the Impact of MRSA Nasal Screen Implementation.

Methodist Health System21 enrolled

Overview

To evaluate the impact of MRSA nasal screen implementation on duration of therapy and cost associated with vancomycin use.

Routine blood and sputum cultures are often obtained inpatient for critically ill pneumonia patients. These tests, however, tend to have a high yield of false positives, leading to an increase in the use of broad spectrum antibiotics, specifically vancomycin. The Methicillin-resistant Staphylococcus aureus(MRSA) nasal screen is an antimicrobial stewardship tool that can be used to guide the treatment of community-acquired, hospital-acquired and ventilator-associated pneumonia. Due to its strong negative predictive value; a negative result can accurately indicate the absence of an MRSA infection in 96% of cases. Long-term treatment with vancomycin in patients with pneumonia is nephrotoxic and not always warranted. The implementation of an MRSA nasal screen in all patients with pneumonia treated with vancomycin has the potential to reduce vancomycin duration of therapy, decrease the risk of adverse effects and decrease the cost associated with vancomycin use.

Study Type

OBSERVATIONAL

Enrollment

Conditions

MRSA

Interventions

Duration of therapyOTHER

The final data will then be compared to determine if the duration of therapy and cost after implementation of the MRSA nasal screen if significantly different from before the implementation of the MRSA nasal screen.

Direct CostOTHER

Direct costs of vancomycin for each treatment arm (in US dollars).

Pharmacokinectic MonitoringOTHER

Number of vancomycin levels drawn for pharmacokinetic monitoring.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age \> 18 years 2. Diagnosis of pneumonia 3. Admission inpatient to Methodist Richardson Medical Center 4. Treatment with vancomycin empirically Exclusion Criteria: 1. Age ≤ 18 years 2. Patients with other confirmed gram positive infections

Locations (1)

Methodist Dallas Medical Center- Clinical Research Institute

Dallas, Texas, United States

Outcomes

Primary Outcomes

Duration of therapy

To analyze duration of vancomycin in days.

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.